OPSUMIT: payments to doctors
Payments that named OPSUMIT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $17.9M
- Providers
- 27,736
- Transactions
- 137,696
- Average per transaction
- $130
The per-transaction average — $130 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 27,736 providers the average total is $645, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $17,385,356 | 97.2% |
| Actelion Pharmaceuticals, Ltd | $268,734 | 1.5% |
| Johnson & Johnson | $168,000 | 0.9% |
| Janssen Scientific Affairs, LLC | $57,803 | 0.3% |
| Janssen Research & Development, LLC | $15,163 | 0.1% |
| Biosense Webster, Inc. | $11 | 0.0% |